Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Insmed (INSM), Biogen (BIIB) and Vertex Pharmaceuticals (VRTX)

Tipranks - Tipranks - Thu Apr 2, 6:10AM CDT

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Insmed (INSM), Biogen (BIIB) and Vertex Pharmaceuticals (VRTX).

End of Quarter Sale - 50% Off TipRanks

Insmed (INSM)

Wells Fargo analyst Benjamin Burnett maintained a Buy rating on Insmed today and set a price target of $177.00. The company’s shares closed last Tuesday at $163.52.

According to TipRanks.com, Burnett is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -3.5% and a 38.5% success rate. Burnett covers the Healthcare sector, focusing on stocks such as Praxis Precision Medicines, Rapport Therapeutics, Inc., and Ultragenyx Pharmaceutical. ;'>

Currently, the analyst consensus on Insmed is a Strong Buy with an average price target of $211.61, which is a 37.5% upside from current levels. In a report issued on March 24, TipRanks – Google also upgraded the stock to Buy with a $159.00 price target.

See today’s best-performing stocks on TipRanks >>

Biogen (BIIB)

In a report released yesterday, Thomas Shrader from BTIG maintained a Hold rating on Biogen. The company’s shares closed last Tuesday at $183.33.

According to TipRanks.com, Shrader is a 4-star analyst with an average return of 6.1% and a 39.9% success rate. Shrader covers the Healthcare sector, focusing on stocks such as Coya Therapeutics, Inc., Alto Neuroscience, Inc., and Acumen Pharmaceuticals. ;'>

Currently, the analyst consensus on Biogen is a Moderate Buy with an average price target of $206.70, a 15.2% upside from current levels. In a report issued on March 29, UBS also maintained a Hold rating on the stock with a $185.00 price target.

Vertex Pharmaceuticals (VRTX)

Wells Fargo analyst Mohit Bansal maintained a Buy rating on Vertex Pharmaceuticals today and set a price target of $550.00. The company’s shares closed last Tuesday at $446.54.

According to TipRanks.com, Bansal is a 5-star analyst with an average return of 9.2% and a 55.6% success rate. Bansal covers the Healthcare sector, focusing on stocks such as Mineralys Therapeutics, Inc., BioMarin Pharmaceutical, and Travere Therapeutics. ;'>

Vertex Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $556.74, representing a 25.6% upside. In a report issued on March 18, Maxim Group also upgraded the stock to Buy with a $575.00 price target.

Read More on INSM:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).